Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + ixabepilone
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + ixabepilone is a combination therapy that pairs an EGFR-targeted monoclonal antibody (cetuximab) with a microtubule stabilizer (ixabepilone). This combination has been investigated primarily for triple-negative breast cancer (TNBC) and pancreatic cancer. Cetuximab targets the epidermal growth factor receptor (EGFR), which plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Ixabepilone is a microtubule-stabilizing agent that disrupts cell division. The combination aims to simultaneously target multiple pathways involved in cancer progression, with cetuximab specifically shown to reduce cancer stem cell (CSC) populations in TNBC tumors.
- Other names
- epothilone B analog (for ixabepilone)
02
Targets
Beyond the preview
Go deeper on cetuximab + ixabepilone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + ixabepilone.